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TWIST1 (TW) is a bHLH transcription factor (TF) and master regulator
of the epithelial-to-mesenchymal transition (EMT). In vitro, TW promotes
mesenchymal change, invasion, and self-renewal in glioblastoma (GBM)
cells. However, the potential therapeutic relevance of TW has not been
established through loss-of-function studies in human GBM cell xenograft
models. The effects of TW loss of function (gene editing and knockdown)
on inhibition of tumorigenicity of U87MG and GBM4 glioma stem cells
were tested in orthotopic xenograft models and conditional knockdown in
established flank xenograft tumors. RNAseq and the analysis of tumors
investigated putative TW-associated mechanisms. Multiple bioinformatic
tools revealed significant alteration of ECM, membrane receptors, signaling
transduction kinases, and cytoskeleton dynamics leading to identification
of PI3K/AKT signaling. We experimentally show alteration of AKT activity and periostin (POSTN) expression in vivo and/or in vitro. For the first
time, we show that effect of TW knockout inhibits AKT activity in
U87MG cells in vivo independent of PTEN mutation. The clinical relevance of TW and candidate mechanisms was established by analysis of the
TCGA and ENCODE databases. TW expression was associated with
decreased patient survival and LASSO regression analysis identified
POSTN as one of top targets of TW in human GBM. While we previously
demonstrated the role of TW in promoting EMT and invasion of glioma
cells, these studies provide direct experimental evidence supporting protumorigenic role of TW independent of invasion in vivo and the therapeutic
relevance of targeting TW in human GBM. Further, the role of TW driving POSTN expression and AKT signaling suggests actionable targets,
which could be leveraged to mitigate the oncogenic effects of TW in GBM.

Abbreviations
AKT, total AKT serine/threonine kinase; GBM, glioblastoma multiforme; PI3K, phosphoinositide-3-kinase; POSTN, periostin; PTEN,
phosphatase and tensin homolog; TW, TWIST1.
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1. Introduction
Despite intensive research and clinical efforts, grade
IV glioblastoma (GBM) remains a highly lethal and
treatment-resistant disease with a median survival time
of approximately 12–16 months. Among the major
barriers to improved outcomes are the diffusely invasive growth of glioma and the difficulty in eradicating
treatment-resistant glioma stem cells (GSCs). These
observations provide strong therapeutic rationale to
target mechanisms which coordinately regulate invasion and GSC phenotypes. We and others have
reported that TWIST1 (TW), a bHLH transcription
factor (TF) and master regulator of epithelial-tomesenchymal transition (EMT), is associated with
increased glioma grade and promotes invasion and
glioma stem cell (GSC) phenotypes (Elias et al., 2005;
Mikheeva et al., 2010; Rahme and Israel, 2015). While
these findings corroborate the well-characterized functional significance of TW in other cancers, the practical importance of TW as a therapeutic target in GBM
has yet to be validated in preclinical GBM models.
Consequently, the TW-regulated molecular pathways
that may contribute to GBM tumorigenicity are also
not established. This understanding is critical however
as a prerequisite to evaluating the potential of therapeutic strategies based on direct inhibition of TW or
its downstream regulated pathways.
In carcinomas, TW activates EMT and promotes
cancer cell invasion, metastasis, and carcinoma stem
cell phenotypes which contribute to treatment resistance and cancer progression (Ramakrishna and Rostomily, 2013) (Sanchez-Tillo et al., 2012). Ectopic
expression of TW in transformed mammary cells promotes EMT, stem cell phenotypes, and tumorigenicity
(Mani et al., 2008), while inhibition of TW decreases
metastasis without altering the growth of the primary
tumor site (Yang et al., 2004). These data support the
critical role of TW for carcinoma malignancy and its
potential importance as a therapeutic target which has
been documented in human nonsmall cell lung carcinoma (NSCLC) xenograft models where TW knockdown inhibits tumor growth (Burns et al., 2013; Lv
et al., 2015; Tran et al., 2012). To date, no anti-TWspecific drugs have been developed, although doxycycline has some activity as a nonspecific inhibition of
TW in lung carcinoma (Qin et al., 2015) and TWspecific RNAi was successfully delivered to breast carcinoma xenografts using a dendrimer (Finlay et al.,
2015). The lack of available clinically validated therapies to target TW reflects the inherent difficulty of traditional approaches to drugging a TF and underscores

TWIST1 regulates glioma malignancy

the rationale to identify downstream signaling as surrogate targets. Although mTOR was identified downstream of TW in a NSCLC xenograft study, additional
actionable surrogate targets for TW have not been
identified in human xenograft-based preclinical models
(Lv et al., 2015).
In human glioma, an EMT-like process is thought to
regulate malignancy, albeit in the absence of metastasis
to distant organs. For instance, gene expression array
studies identified a mesenchymal stem cell phenotype in
human GBMs (Tso et al., 2006) and distinct proneural,
proliferative, and mesenchymal gene expression signatures among malignant grade III and IV human gliomas (Phillips et al., 2006). The mesenchymal GBM
signature is associated with poor prognosis, increased
angiogenesis, and tumor recurrence (Morokoff et al.,
2015), and a proneural-to-mesenchymal transition
(PMT) commonly accompanies tumor progression and
treatment resistance (Segerman et al., 2016). As stated
above, we and others have reported functional roles of
TW in glioma to promote EMT-associated phenotypes
of invasion and cancer cell stemness consistent with
those reported in carcinomas (Kubelt et al., 2015;
Mikheeva et al., 2010). However, the potential therapeutic benefits of targeting TW have not been directly
tested in vivo in human GBM xenograft models. This is
a critical first step for establishing therapeutic relevance
given that functional phenotypes of TW inhibition as
currently understood in vitro may not fully translate to
a therapeutic benefit in vivo.
Therefore, as a first step toward establishing the
potential therapeutic benefits of targeting TW in
GBM, we studied the effects of TW loss of function
on tumorigenicity in xenograft models using the established human U87MG and GBM4 GSC lines. In both
cell lines, TW loss of function mitigated glioma cell
tumorigenicity with concurrent inhibition of periostin
(POSTN) expression and PI3K/AKT signaling.
Together, these findings provide evidence for the relevance of TW as a potential therapeutic target in GBM
and identify potentially actionable surrogate therapeutic targets.

2. Methods
2.1. Cell lines
U87MG cells were acquired from ATCC- and
U87MG-derived cell lines were maintained in DMEM/
F12 with 10% FB Essence (VWR, Radnor, PA, USA).
GBM4 was obtained from H. Wakimoto (Wakimoto
et al., 2009).
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2.2. CRISPR gene editing, stable, and inducible
shRNA knockdown
Two TW targeting gRNA were cloned in pCLIP harboring Cas9 fused to Flag tag (puromycin resistant)
and Cas9 targeting gRNA (without Cas9) tagged with
RFP (Transomics, Huntsville, AL, USA). Multiple
clones were selected for each gRNA and used as a
pool. Two independent shRNA for stable (pLKO;
Sigma, St. Louis, MO, USA) and conditional knockdown of TW (shTWi in pTRIPZ; Dharmacon, Lafayette, CO, USA) and corresponding vectors harboring
scrambled control sequences were used for TW knockdown experiments. For rescue experiments, cells were
transduced with retroviruses harboring TW in LXSN
or empty vector (Mikheeva et al., 2010).
2.3. Orthotopic and flank xenograft models
Animal experiments were performed according to
approved University of Washington IACUC protocols.
Nude mice were injected subcutaneously with 600 000
U87MG cells harboring conditional shTWi or shScri
knockdown vector. After 14 days, animals were
switched to doxycycline supplemented chow (Envigo,
Huntingdon, UK) and sacrificed after 3, 5, or 10 days.
Tumor was measured with caliper, and volume was
calculated (Mikheev et al., 2004). Intracranial injection
of cells (100 000–150 000 cells per animal) were performed as described previously using stereotactic frame
(Mikheev et al., 2015). Peri-operative care included
approved anesthesia and analgesia. Animals were sacrificed when developed clinical manifestation. To avoid
animal suffering, the time of sacrifice was used as a
surrogate for survival analysis. GFP-positive tumor
fragments identified under fluorescence dissecting
microscope were digested with trypsin and plated in
media or snap-frozen for RNA or protein extraction
using RNAeasy kit (Qaigen, Hilden, Germany) or
RIPA buffer, respectively.
2.4. RNAseq analysis
Four biological replicas for each group of cells and
eight individual tumors derived from the same cells
in vivo are included in the study. RNAseq reads were
analyzed using FastQC for quality control. Short reads
were aligned to the hg38 reference genome. FPKMs
(fragments per kilobase per million mapped reads)
(Mortazavi et al., 2008) were determined for all RefSeq
genes using CuffLinks. Read counts were obtained
using HTseq (Anders et al., 2015). Differential expression analysis was performed based on the read counts,
1190

using DESeq2 (Love et al., 2014) modeling the raw
read counts data to follow a Negative Binomial distribution. The procedure of Benjamini and Hochberg
(1995) was used for multiple testing to estimate the
FDR. The differentially expressed genes were selected
by two criteria, absolute fold change larger than 2 and
adjusted P-values (FDR) less than 0.05. RNAseq data
are deposited in Gene Expression Omnibus (GEO)
with the accession number GSE106159.
2.5. Bioinformatics
Differentially expressed genes were analyzed using
GoMiner and Ingenuity pathway analysis for gene categories and canonical pathways. The PI3K/AKT signaling pathway interactions are downloaded from
KEGG (Kanehisa and Goto, 2000) and DLRP (Graeber and Eisenberg, 2001) databases. The gene–gene
interactions of PI3K/AKT pathway and fold change
were visualized using Gephi (Mathieu et al., 2009).
2.6. Statistical analysis
Median survival of tumor-bearing animal cohorts was
compared by logrank test using Prism 7 (GRAPHPAD
Software, La Jolla, CA, USA).
2.7. Additional methods
Details on cell authentication, RNAseq, immunofluorescence, qRT-PCR, western blotting, and antibodies
are provided in Appendix S1. Methods for histology,
invasion, and proliferation assays were previously
described (Mikheev et al., 2009, 2012, 2015; Mikheeva
et al., 2010).

3. Results
3.1. Disruption of TW protein expression by gene
editing inhibits U87MG tumorigenicity
To establish the potential therapeutic relevance of TW
inhibition in GBM, we first studied the effects of TW
protein knockout in the U87MG cell line. U87MG
was chosen for the initial experiments based on its
high levels of TW expression, rapid and reproducible
tumorigenicity, and ease of subcloning required for
selection of CRISPR/Cas9-mediated knockout clones.
To confirm the effects of TW loss of function, TW
knockdown was also studied in the GBM4 GSC line
(see below). Stable selection of TW-specific gRNA/
Cas9 constructs (TW-A and B) in uncloned U87MG
cells resulted in near complete loss of TW protein
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compared to controls with nontargeting gRNA/Cas9
constructs (dNT) (Fig. S1A). Upon orthotopic implantation, we observed a 29% prolonged survival in animals harboring the U87MG dTW-A cells compared to
dNT control (Fig.S1B). The gross appearance of
tumors examined at terminal time points was similar
(Fig.S1C), but examination of dTW-A tumor-derived
cells demonstrated high levels of TW and low Cas9
protein expression compared to U87MG dTW-A cells
before injection (Fig.S1D). The reduction in Cas9 was
confirmed by immunostaining of tumor sections
(Fig. S1E). These results indicated that a small minority of cells retaining TW expression (and low or absent
Cas9) provided a selection advantage for U87MG
growth in vivo and that the increased survival likely
resulted from a smaller number of TW competent
cells.
To eliminate the outgrowth of rare TW+ cells, we
subcloned control U87MG dNT and dTW-A cells.
Mutations and elimination of TW protein were confirmed through direct sequencing across the gRNA site
and western blot of selected clones, respectively
(Table S1 and Fig. S2). Using algorithm available at
KBiobox, we identified two high-risk off-target genes
for the TW-A gRNA, USP35, and EXOC4 (Fig. S3).
Targeted sequencing found a single mutation only for
USP35 in one clone, which was excluded from further
experiments (Table S1). Cells were then pooled from 10
random control subclones (designated U87MG dNTsc)
and 6 subclones lacking TW expression (U87MG dTWAsc) for xenograft experiments (Fig. 1A, lanes 1, 2).
After orthotopic implantation of equal numbers of control and TW-deficient cells, we found that dTW-Asc
implanted animals showed a survival increase of 88%
compared to animals implanted with control cells (33
versus 17.5 days, respectively; P = 0.0002; Fig. 1B).
Stable loss of TW in U87MG dTW-Asc-derived tumors
was confirmed in tumor-derived cells (Fig. 1A, lanes 57 versus 3, 4). Of interest, U87MG dTW-Asc-derived
tumors generated a partially exophytic versus intracranial growth pattern (Fig. 1C). Histologic examination
revealed subtle differences with U87MG dNTsc tumors
harboring larger more mesenchymal appearing cells,
while U87MG dTW-Asc-derived tumors had smaller
and more densely packed cells. No tumor cell invasiveness is noted at the tumor brain interfaces independent
of TW status (Fig. S4). Re-expression of TW in dTWAsc cells after CRISPR mediated deletion of Cas9
(Fig. 1D) rescued the effects of TW deletion evidenced
by a 69% reduction in animal survival compared to
U87MG dTw-Asc cells harboring an empty expression
vector (13 versus 22 days, respectively; P = 0.0018)
(Fig. 1E) and reversion to exclusive intracranial growth
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patterns (not shown). With a second gRNA, TW-B, we
validated and pooled six subclones (Table S2; Fig. 1F;
no high-risk off-target genes were identified) and found
a similar decrease in tumorigenicity after implantation
(Fig. 1G) and accompanying decreases in tumor growth
(Fig. 1H). In vitro invasion assay did not reviled effect
of TW knockout of cell invasion in serum-free conditions (not shown). Because U87MG tumors are not
invasive in vivo, we concluded that inhibition of TW is
due to alteration of tumorigenicity and not invasion.
Finally, to determine the effect of TW loss of function
after tumor formation we showed that doxycycline
induced TW knockdown in established U87MG flank
tumors reduced subsequent tumor growth from a mean
of 300 mm3 to 75 mm3 (P = 0.0114; Fig. S5). Together,
these data strongly support the physiologic relevance of
TW for U87MG tumorigenicity and potential relevance
of TW as a clinical target.
3.2. Identification of TW-regulated genes and
pathways
To identify mechanisms regulated by TW which contribute to tumorigenicity, we performed RNAseq
analysis of U87MG dNTsc vs dTW-Asc cells growing
in vitro and their respective orthotopic xenograft
tumors harvested at terminal time points. A disambiguation analysis was used to eliminate confounding
reads from mouse mRNA in xenografts (Ahdesm€
aki
et al., 2017). Comparison of TW-associated differentially expressed genes (DEGs) from cell lines and
tumors identified a largely distinct set of DEGs
unique to the cell lines or tumors with a smaller number common to both (Fig. S6, Table S3). To identify
physiologically relevant candidates, we analyzed all
DEGs detected in tumors. GoMiner (Zeeberg et al.,
2003) analysis identified TW-regulated DEGs in
tumors enriched for genes encoding extracellular
space (growth factors, cytokines, extracellular matrix
proteins, proteins with metallopeptidase activity) and
cell membrane (growth factor receptors, integrins,
tumor necrosis factor receptors, and cytokine receptors) proteins (Fig. 2A). This analysis indicated that
TW might have functional roles in modifying and/or
responding to the in vivo tumor microenvironment,
cell–cell interactions, ECM-cell signaling, and
response to growth factors. Ingenuity Pathways Analysis (IPA) identified canonical pathways related to
glioblastoma signaling and invasiveness indicating
that TW has broad effect on U87 glioma cells
(Fig. 2B). Among canonical IPA pathways, we identified PI3K/AKT, which is part of the Glioma Invasiveness Signaling and GBM signaling networks.
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Fig. 1. TWIST1 promotes tumorigenicity of U87MG cells. Pooled subclones of TW-deleted U87MG cells are less tumorigenic: (A)
Confirmation of TW expression and knockout retained in tumor-derived cells from animals injected with control (dNTsc, lanes 3,4) and TW
knockout (dTW-Asc, lanes 5, 6, 7) cells. Cells before injection shown in lanes 1 and 2. (B) Extended survival of animals injected with a
pooled subclones with confirmed TW mutation (dTW-Asc) and knockout compared to pooled control subclones (dNTsc). (C) Differential
intracranial versus exophytic growth patterns of tumors generated by U87MG dNTsc and dTW-Asc cells, respectively. (D) Overexpression of
TW or empty vector in U87MG dTW-Asc cells after self-deletion of Cas9 (dTW-Asc dCas9). (E) Survival analysis demonstrating TW reexpression in TW-deleted cells significantly reduced median survival compared to TW null control cells. (F) Confirmation of Cas9 and TW
knockout in the pooled U87MG subclones expressing the independent TW-B gRNA (dTW-Bsc) before injection. (G) Survival curves showing
marked prolongation of survival after implantation of TW-deficient cells (U87MG dTW-Bsc dCas9) compared to control. (H) Gross
appearance of representative TW-deleted (dTW-Bsc dCas9) and control tumors (dNTsc dCas9).

Consistent with GO cytokine categories, we identified
IL-6 and IL-8 pathways, which signal through JAK/
Stat and PI3K/AKT pathways. Alteration of extracellular components is consistent with Integrin and ILK
signaling which also signal through PI3K/AKT.
(Fig. 2B). Together, GoMiner and IPA suggested that
TW likely to promote malignant phenotypes through
coordinated regulation of genes related to ECM,
membrane receptors, signaling transduction kinases,
and cytoskeleton dynamics all of which in part function through PI3K/AKT signaling. TW has been
1192

linked to this mechanism (Martini et al., 2014), and
therefore, we used the Kyoto Encyclopedia of Genes
and Genomes (KEGG) database to perform network
analysis of PI3K/AKT-related DEGs. We found that
functionally related subsets of PI3K/AKT-related
DEGs were markedly upregulated in TW wild-type
versus TW knockout tumors and that this upregulation was more pronounced in tumor samples compared with cell lines in vitro (Fig. 2C, D, Fig. S7).
Together, our observations indicate that TW function
can be influenced by the environmental context
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Fig. 2. TWIST1 regulates genes associated with ECM and PI3K signaling. (A) Heat map of GO categories of TW DEGs identified by RNAseq
in U87MG tumors. GO analysis shows enrichment for categories related to ECM constituents, ECM protein interactions, membrane
receptors, growth factor, and cytokine signaling. Genes comprising the significantly altered GO categories (P < 0.05) are listed in Table S4.
Scale: Yellow and red show direction of gene expression change (down and up, respectively). POSTN is identified in multiple GO categories
(arrow). (B) IPA analysis of DEGs. Examples of canonical pathways identified by IPA analysis and corresponding Z-scores are shown. (C,D)
Comparison of in vitro (C) and in vivo (D) TW-regulated PI3K network analysis constructed from TW-dependent DEGs using KEGG.
Individual genes (nodes), gene interactions (edges), and proportional absolute log2 fold changes (node size) and direction of change in
control versus deleted tumors [upregulation—red (log2 > 0.5-fold); downregulation—green (log2 < -0.5-fold); no change (white)] are shown.
Analogous subnetworks showing the largest changes are circled; growth factor/RTKs (blue), ECM proteins/Integrins (black), and cytokines/
cytokine receptors (green). Enlarged version of this panel is shown in Fig. S7.

(in vitro versus in vivo) and that an in vivo dependent
activation of PI3K/AKT-related genes may contribute
to its impact on tumorigenicity.
3.3. TW-mediated regulation of AKT and
periostin
To establish PI3K/AKT signaling as a downstream target,
we investigated TW-dependent regulation of AKT phosphorylation in U87MG cells and tumors. Marked inhibition of T308 and S473 AKT phosphorylation was
observed in tumors but not cell lines prior to implantation
(Fig. 3A) and inhibition was reversed in tumor-derived
cells re-expressing TW (Fig. 3B). Collectively, these data
demonstrated that TW-dependent growth of U87MG cells

in vivo was associated with activation of AKT. In other
cancers, TW regulates AKT signaling through phosphoactivation (Li and Zhou, 2011) (Roberts et al., 2016) as
well as transcriptional upregulation (Cheng et al., 2007).
Here, TW deletion did not alter AKT gene expression (not
shown), and therefore, in U87MG TW appears to primarily regulate AKT signaling through phosphorylation.
We previously showed that POSTN is important for
glioma tumorigenicity (Mikheev et al., 2015). POSTN
is also known to activate AKT (Morra and Moch,
2011). To determine whether POSTN is a downstream
target of TW in the U87MG model, we analyzed
POSTN expression in U87MG cell lines and tumors.
We found that POSTN mRNA expression levels were
dramatically increased in U87MG derived tumors
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Fig. 3. TWIST1 knockout regulates POSTN expression, AKT phosphorylation. (A) Western blot analysis of AKT phosphorylation (T308 and S473) in
cells before implant (lanes 1,2) and in individual control (lanes 3–6) and TW-deleted (lanes 7–9) tumors. (B) Western blot analysis of AKT
phosphorylation (T308 and S473) in tumor-derived early passage U87 dTw-Asc dCas9 cells re-expressing TW (lanes 1–3) or with TW deleted (lanes
4,5). (C). POSTN mRNA expression (FPKM values from RNAseq) in U87MG cells in vitro (cells) and in vivo (Tumors) with endogenous (dNTsc) or
deleted TW (dTW-Asc). (D) Western blot detection of POSTN protein in individual control dNTsc (lanes 1–4) and dTW-Asc tumors (lanes 5–7).
Levels of POSTN protein expression in cells in vitro are below detection limits (not shown). (E) Analysis of POSTN expression in tumors with
deleted TW (dTW-Asc+LXSN) (lanes 1–3) and in tumors with exogenous TW overexpression (dTW-Asc + TW) (lanes 4–7).

compared with cell lines in vitro (~1200-fold; mean
FPKM 750 vs 0.4, respectively; P = 0.00024) with a
marked ~43-fold inhibition of POSTN expression in
TW-deleted tumors (FPKM 750 vs 17.5; P = 0.00024)
also reflected in western blot analysis (Fig. 3C,D).
Inhibition of POSTN protein expression in TW-deleted
tumors is reversed by TW overexpression (Fig. 3E).
Therefore, as for AKT, POSTN is an in vivo target of
TW regulated on mRNA level in U87MG.
3.4. TW knockdown inhibits GBM4 glioma stem
cell tumorigenicity, POSTN expression, and AKT
activity
To extend our observations in U87MG to a GSC line,
we studied the effects of TW knockdown in the GBM4
1194

GSC line. Expression of TW shRNA (shTW) achieved
significant knockdown of TW and POSTN mRNA
(~75% and ~85%, respectively) and protein levels
(Fig. 4A,B) and 40% reduction in invasion (Fig. 4C).
TW silencing did not affect cell proliferation in vitro
(Fig. 4D), suggesting that differences in cell invasion
are not influenced by alteration of cell proliferation.
We observed marked improvement in median survival
of animals injected with GBM4 shTW cells compared
to control (135 days versus 82 days, respectively;
P = 0.0027, Fig. 4E). A second TW shRNA targeting
the 30 UTR also inhibited POSTN expression, which
was partially re-established by re-expression of TW
(Fig. 5A). Knockdown of TW and corresponding inhibition of POSTN also resulted in reduced AKT phosphorylation, which was restored with re-expression of
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Fig. 4. TWIST1 promotes tumorigenicity and upregulates POSTN in GBM4 GSCs. (A) qRT-PCR quantification of TW and POSTN mRNA
levels after TW knockdown in GBM4 with TW-specific shRNA (shTW) compared to scrambled shRNA control (shScr). (B) Western blot of
TW (whole cell lysate) and secreted POSTN from control (shScr) and TW knockdown (shTW) GBM cells. (C) Quantification of matrigel
transwell invasion assay with representative membranes shown after 63 h. (D) Proliferation assay of GBM4 shScr vs shTW cells. Absolute
cell number was measured at indicated time points. Number of cells plated is shown at time ‘0’. (E) Kaplan-Meier curves comparing median
survival of host nude mice after orthotopic implants of control (shScr) and TW knockdown (shTW) (135 vs 82 days, respectively;
P = 0.0027).

TW (Fig. 5B). Bar diagram demonstrates significant
averaged change in AKT phosphorylation at Thr308
and Ser473. Expression of the 30 UTR shTW in GBM4
cells markedly prolonged survival (undefined at
132 days versus 84.5 days for controls; P = 0.0014),
while TW re-expression restored tumorigenicity to
levels comparable to controls (median survival 94 days)
(Fig. 5C). To examine effects of TW early after cell
implantation, we examined expression of activated caspase 3 at 10 days postimplantation. TW knockdown
decreased the number of viable cells with corresponding increases in activated caspase 3 + tumor cells compared to controls (Fig. 5D; middle and top panel,
respectively). Re-expression of TW completely reversed
this effect (Fig. 5D; lower panel, Fig. 5E). These data
demonstrated that TW loss of function in a second
GBM cell line resulted in a similar decrease in tumorigenicity, POSTN expression, and AKT signaling as
observed above for U87MG.
3.5. TW expression correlates with GBM patient
survival and POSTN expression
To establish potential clinical relevance of TWmediated regulation of POSTN, we investigated the

relationship between TW expression and GBM patient
survival using the TCGA database. TW expression
levels distribution across 525 samples in the microarray dataset and in samples with top 10% and bottom
10% levels of TW expression (Fig. S8 A, B) were used
for survival analysis. We selected to use patient top
and bottom TW expressers as it mirrors overexpression and under-expression in the animal experiments.
The array counts generated by TCGA were used without additional processing. Patient median survival was
significantly decreased in patients with high (top 10%)
versus low (bottom 10%) TW expression levels
(Fig. 6A; 318 vs 442 days, respectively; P = 0.0331).
Similar results were observed in the TCGA RNAseq
dataset (Fig. S8C). Similarly by comparing high TWexpressing GBMs with all other GBMs in the TCGA
data set based on a Z-score cutoff of 2 (http://www.cb
ioportal.org), we found a comparable level of significance (340 vs 435 days, P = 0.0307, n = 487; data not
shown). A similar impact of high TW expression on
shortened survival was reported using REMBRANDT
data comprised of all glioma grades (Nordfors et al.,
2015) and in NSCLC (Lv et al., 2015). These observations suggest that high levels of TW expression have a
generic effect on increasing cancer malignancy.
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Fig. 5. TWIST1-dependent AKT phosphorylation in GBM4 GSCs correlates with tumorigenicity in vivo. (A) Marked knockdown TW and
POSTN protein expression in GBM4 cells (whole cell lysates) expressing shScr control or a TW-specific 30 UTR shRNA (lanes 1,2
respectively). Re-expression of TW open reading frame TW partially restores POSTN expression compared to empty vector (lanes 3, 4).
U87MG is shown for comparison of TW expression and lack of POSTN expression (lane 5). (B) TW knockdown in GBM4 reduced AKT
phosphorylation (T308 and S473). Overexpression of TW increases AKT phosphorylation. (C) 30 UTR-mediated TW knockdown increased
survival (>125 days versus 84.5 days; P = 0.0014), while re-expression of TW restores the control tumorigenic phenotype (median survival
94 days). (D) Representative images of tissue sections from short-term (3-4 animals/group) implants of control (top row), TW 30 UTR
knockdown (middle row), and TW re-expression (bottom row) in GBM4 cells. Animals were sacrificed 10 days after intracranial cell injection.
Staining was performed for total nuclei (DAPI), apoptotic cells (active caspase 3), and tumor cells (HuNu). (E). Quantification of active
caspase-positive cells in implants of control cells (shScr+LXSN), cells with TW knockdown (shTW+LXSN), and TW-overexpressing cells
(shTW+TW). Percent of active caspase-3-positive cells is calculated relative total number of HuNu-positive cells in the implant. P value
calculated by two-tailed T-test.

To establish potential mechanistic links between TW
and POSTN in GBM, we generated a TW transcriptional regulation model for all protein-coding genes
using TCGA microarray data as input (Ament et al.,
2016). By only considering transcription factors for
which footprints are found in ENCODE DHS data,
we performed LASSO regression to identify the top
targets of TW. POSTN was found to be a likely target
for TW, having the third best beta-coefficient among
all putative TW targets (Fig. 6B). Further, a significant
correlation between TW and POSTN expression levels
was detected in a set of 38 human gliomas of various
grades (Fig. 6C) supporting potential regulatory interactions between the two genes. Similar significant correlations were observed in Rembrandt and TCGA
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datasets (r = 0.531, P = 0.00001 and r = 0.414,
P = 0.00001; respectively) (Table S5). In the TCGA
dataset (U133A microarrays; n = 358), we also determined that the significant correlation between TW and
POSTN is driven largely by high correlations in the
proneural (R = 0.5; P = 0.000075; n = 57) and mesenchymal (R = 0.469; P = 0.0002, n = 58) but not neural or classical GBM subtypes (Table S5). Together,
these results demonstrated that high TW expression is
associated with increased GBM malignancy and
POSTN expression supporting the broader potential
clinical relevance of TW-mediated regulation of
POSTN for malignancy and that targeting this signaling axis may be most productive in specific GBM
subtypes.

Molecular Oncology 12 (2018) 1188–1202 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

A. M. Mikheev et al.

TWIST1 regulates glioma malignancy

Fig. 6. TWIST1 expression levels predict survival and correlate with POSTN expression. (A) Kaplan–Meier analysis of patient survival
stratified by TW high and low expression levels (n = 53 each group). (B) List of top ranking genes in TW transcriptional network analysis of
TCGA TW DEGs identifies POSTN. (C) Correlation between TW and POSTN expression in a group of 39 glial tumors (9 grade II, 3 grade III,
and 27 grade IV). DCt values were determined by qRT-PCR.

4. Discussion
TW is a well-established master regulator of EMT in
carcinoma (Qin et al., 2012; Zhao et al., 2017; Zhu
et al., 2016), and loss of TW function has been shown
to decrease tumorigenicity in lung carcinoma xenografts (Burns et al., 2013; Lv et al., 2015; Tran et al.,
2012), but existing data on TW function in glioma is
restricted to in vitro functional analysis or correlations
of expression in human tissue samples with clinical features of malignancy or outcome (Elias et al., 2005;
Mikheeva et al., 2010; Nordfors et al., 2015). The purposes of this study were to demonstrate the potential
therapeutic relevance of targeting TW in human GBM
and identify mechanisms downstream of TW. To
establish the potential therapeutic relevance of TW, we
tested the impact of TW loss of function in human
GBM cell lines on tumorigenicity and employed transcriptomic analysis to identify TW-regulated signaling
mechanisms. Also, we identified downstream TW signaling mechanisms, which might serve as surrogate
targets to inhibit function. Our results provided the

first in vivo evidence supporting the clinical relevance
of targeting TW in GBM and confirmed POSTN and
AKT signaling as candidate effectors of TW function
in these models. Importantly, we also validated the
clinical relevance of POSTN as a putative TW target
gene in human glioma and GBM gene expression databases.
Using either CRIPSR/Cas9 gene editing or shRNA
knockdowns in two GBM cell lines, we observed consistent decreases in tumorigenicity and selection of
TW-expressing cells in uncloned cell pools (Fig. S1).
Of interest, the elimination of Cas9 resulted in a slight
increase in tumorigenicity (Fig. 1B vs Fig. 1E). This
may reflect an inhibitory effect of constitutive Cas9 on
tumorigenicity through its recognized toxic or off-target effects (Morgens et al., 2017) or differences in
malignant potential of clones selected in the different
experiments. Regardless, the consistent impact of TW
loss of function and rescue on tumorigenicity with TW
re-expression supports its critical physiologic role for
U87MG malignancy. TW loss of function also
decreased tumorigenicity in the GBM4 GSC line,
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suggesting that TW functions may be critical for
malignancy in clinically relevant GSCs. Overall, the
consistent results observed in both cell lines employing
rigorous controls for nonspecific effects provide strong
preliminary evidence for the potential therapeutic relevance of inhibiting TW in GBM. To validate our current findings and more closely simulate the clinical
setting, future studies will employ conditional
inhibition of TW in established orthotopic GSC
xenografts.
Of the few studies reporting on the effects of direct
TW inhibition in human cancer xenograft models, all
involve the use of human NSCLC lines (Burns et al.,
2013; Lv et al., 2015; Tran et al., 2012). Lv et al.
(2015) and Tran et al. (2012) using shRNA-mediated
TW knockdown in single cell lines report decreased
growth rate and tumorigenicity, respectively, in flank
models (Lv et al., 2015; Tran et al., 2012). Using five
NSCL lines, Burns et al. (2013) showed that shRNAmediated inhibition of TW uniformly decreased tumor
growth rates through activation of oncogene-induced
senescence independent of specific oncogene drivers or
p53 mutation status. The cell lines used in the present
study also harbor different driver mutations (PTEN
for U87MG and MYC amplification for GBM4) and
p53 mutations status (U87MG WT and GBM4 mutant
(not shown)) yet demonstrate similar reduction in
tumorigenicity with TW loss of function. TW can
interact with WT p53 and promote its degradation
(Piccinin et al., 2012) indicating potential unique functional significance in p53 WT tumors. However, our
previous study (Mikheev et al., 2017), the present
study, and others (Burns et al., 2013) demonstrate that
TW can support tumorigenicity independent of p53
mutational status and as shown in a mouse model of
skin cancer (Beck et al., 2015), TW may have p53dependent and p53-independent functions that drive
malignancy. These reports and our observations here
provide rationale for additional studies in GBM to
establish the broader scope of oncogenic contexts in
which TW may be a therapeutic target.
The downstream effects of TW inhibition have not
been rigorously characterized in human xenograft
glioma models. Global analyses of TW loss of function
in a cranial mesoderm development model identified
cell–matrix interaction, regulation of EMT, blood vessel morphogenesis, and anti-apoptosis via PI3K/AKT
as the top four enriched processes (Bildsoe et al.,
2016), which strikingly mirror the findings of our transcriptome analysis of TW knockout in U87MG xenografts. Informed by this analysis, we also validated an
association between TW-dependent tumorigenicity and
regulation of AKT signaling and POSTN expression.
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Because PTEN mutation is recognized as leading event
in activation of AKT signaling in U87MG cells, our
results show for the first time that TW knockout is
sufficient to interrupt effect of PTEN mutation.
Gene expression profiles of U87MG cells were
markedly influenced by in vivo growth and revealed
TW-mediated regulation of POSTN and AKT signaling not evident in cells prior to implantation. This
observation underscores the importance of studying
gene function in the more relevant in vivo physiologic
context as recently shown in a screen for cancer drivers in GSC models (Miller et al., 2017). A similar
analysis of GBM4 xenografts was practically limited
by the invariable growth and small tumor sizes of
TW-deficient GBM4 tumors, yet these cells demonstrated TW-dependent regulation of POSTN and AKT
without in vivo selection. This may indicate that specific oncogenic signaling activity may be altered by
in vivo selection in a cell type-specific fashion, which
can be established with further investigation.
The functional relevance of POSTN for TW function is suggested by similar inhibition of GBM4 cell
survival in vivo observed in prior analysis of POSTN
(Mikheev et al., 2015) and TW loss of function shown
here. Our analysis of human GBM TCGA data provided evidence that POSTN is regulated by TW in
human glioma, supporting the clinical relevance of
findings in our xenograft studies. How TW might regulate POSTN expression in our models requires further investigation but may involve mechanisms
identified in other biological models. For instance,
Oshima et al. demonstrated binding of TW to an
E-box site within the mouse POSTN promoter
(Oshima et al., 2002) and Connerney et al. demonstrated that POSTN expression is highly dependent on
the TW homo- or heterodimerization motifs (Connerney et al., 2006). In GBM and other cancers, POSTN
signals through integrin receptors and in other cancers
can activate AKT (Bao et al., 2004; Mikheev et al.,
2015; Ruan et al., 2009). Of interest, AKT-dependent
phosphorylation of TW at Ser42 is reported to inhibit
p53 activity (Vichalkovski et al., 2010), suggesting
reciprocal interactions between TW and AKT may
contribute to malignancy through additional mechanisms of particular relevance in p53 wild-type GBM
cells such as U87.
Together, these observations support a putative
TW-POSTN-AKT signaling axis in human GBM,
which could potentially be targeted to disrupt TWmediated tumorigenicity. We previously demonstrated
that POSTN loss of function phenocopies TW loss of
function as shown here (Mikheev et al., 2015). In
addition, in a Cre-Lox TW mouse glioma model we
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found that TW deletion inhibited tumorigenicity when
neural progenitor cells (NPCs) were transformed with
Ha-RASV12 overexpression and p53 knockdown but
not with co-overexpression of Ha-RASV12 and myristoylated AKT (a constitutively phosphorylated form)
(Mikheev et al., 2017). The latter finding suggested
that TW acts upstream of AKT accounting for the
lack of effect when transforming NPCs with the constitutively activated myrAKT (Zhao et al., 2003). This
is consistent with our current findings here that TW
loss of function inhibits the activation of endogenous
AKT in human GBM cells, suggesting that TW acts
upstream of AKT. Of interest, TW loss of function
resulted in altered AKT activation regardless of
PTEN status (U87 is PTEN deficient and GBM4 is
PTEN wild-type). This further implies that TW may
function downstream of PTEN through mechanisms
such as mTORC2 or PDK1 which proximately regulate AKT phosphorylation (Manning and Toker,
2017). Another open question is whether TW regulates AKT and malignancy in GBM through specific
AKT isoforms as has been shown for TW-driven
EMT by promoting TW degradation in breast cancer
cells (Li et al., 2016). Taken together, our current
findings provide support for future studies that more
precisely dissect the signaling interactions between
TW, POSTN, and AKT and establish points of regulation expected to provide mechanistic insight and
potential translational relevance for targeting TWdriven GBM malignancy.

5. Conclusions
In this study, we took a critical step toward establishing the potential of TW as a therapeutic target in
GBM by documenting inhibition of tumorigenicity
with TW loss of function in human xenograft models.
In addition, we identified POSTN and AKT signaling
as mechanisms downstream of TW, which may expand
the therapeutic options to indirectly abrogate TW
function. The use of dendrimer delivery of a TW-specific RNAi has shown theoretical potential in a breast
carcinoma model (Finlay et al., 2015). Recently, TW
inhibitor that phenocopied genetic loss of TW by
inducing oncogene-induced senescence or apoptosis
was described (Yochum et al., 2017). Strategies to target the POSTN/AKT axis downstream of TW could
utilize the following approaches alone or in combination: Delivery of POSTN blocking antibodies demonstrated to have activity in preclinical cancer models
(Zhu et al., 2011), blockade of POSTN binding integrin receptors with cilengitide (Mikheev et al., 2015),
and available AKT inhibitors.
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